Plain-English translation of NCT07503652 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a medication called Xeligekimab to see if it can help people with palmoplantar pustulosis—a chronic condition that causes painful, itchy pustules and scaling on the palms and soles of the feet. Many patients with this condition don't respond well to older treatments, and researchers believe this new biologic medication might offer better relief.
Current treatments for this condition, like steroids and older immunosuppressive drugs, often don't work well enough or cause side effects with long-term use. This trial is exploring whether the medication could become a new option for people whose symptoms have not improved with standard care.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive Xeligekimab treatment as part of this study. The trial involves a small group of 10 people total, and you would be closely monitored by the research team to see how your skin responds and whether your symptoms improve. Your doctors will track your progress using standardized skin assessments and quality-of-life questionnaires throughout the study.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
China